Human muscle cells

Consistent, defined and scalable human iPSC-derived skeletal myocytes for musculoskeletal disorders (MSD) research

Significant advances are being made in the study of musculoskeletal disease. Where conditions like Duchenne muscular dystrophy (DMD) were once seen as untreatable, hope now swells as gene therapies advance into the market. Critical to the study and treatment of conditions like DMD is the use of physiologically relevant musculoskeletal disease models. As immortalised human muscle cell lines can be difficult to access, and animal myoblast cell lines are phenotypically distinct from their in vivo counterparts, many in the field are now turning to a more physiologically accurate source of cells: iPSC-derived myocytes [1].

bit.bio’s deterministic cell programming technology (known as opti-ox™) makes it possible to generate functional human skeletal muscle cells with unmatched lot-to-lot consistency from iPSCs on a nearly limitless scale (all without the challenges typically associated with myocyte differentiation). Both wild-type and disease-specific myocytes are readily available, enabling researchers to study skeletal myocytes in vitro with ever more translational power.

Leveraging genetically matched controls, human iPSC-derived skeletal myocytes containing DMD mutations can be used to screen prospective therapeutics, including exon-skipping therapies and other advanced drug modalities.

Strengthen your research with bit.bio’s human iPSC-derived skeletal myocytes.

Browse relevant resources

Brochure

ioSkeletal Myocytes

bit.bio

Download

Poster

Genotype and phenotype validation of an isogenic human iPSC-derived neuronal model of Huntington’s Disease

Oosterveen, et al

bit.bio

2022

View poster

Poster

Stimulating 3D Skeletal Muscle Microtissues in a Novel Perfusable Microphysiological System with Integrated Electrodes

Dr Mitchell Han

Bi/ond

2023

View poster

Poster

Generation of human iPSC-derived Duchenne muscular dystrophy skeletal myocytes suitable for 3D functional studies and investigating methods for dystrophin restoration

Bernard, et al

bit.bio

2024

View poster

Publication

Reprogramming the stem cell for a new generation of cures

Davenport A, Frolov T & Kotter M

Drug Discovery World

2020

Publication

Functional neurological restoration of amputated peripheral nerve using biohybrid regenerative bioelectronics | Publication

Rochford and Carnicer-Lombarte et al.

Science Advances

2023

Featuring opti-ox enabled skeletal myocytes iPS cell line

Talk

CRISPR and the Art of Perturbation Screening: Unbiased functional genomic screening meets the best human cellular models

Kam Dhaliwal | SVP Strategic Alliances | bit.bio

Talk at ELRIG CRISPR in Drug Discovery

Watch now

Talk

Consistent and scalable human iPSC-derived cells for in vitro disease modelling and drug discovery

Kam Dhaliwal | SVP Strategic Alliances | bit.bio
Dr Thomas Moreau | Head of Research | bit.bio

Talk at ELRIG Drug Discovery Digital

Watch now

Talk

Using human iPSC-derived ioSkeletal Myocytes and ioMotor Neurons to model complex neuromuscular systems in vitro

Dr Grace Cooper | Senior Scientist | bit.bio

Human Cell Forum 2025
Session 1 Track 2 | From cells to systems: Building human iPSC-derived models of pain, neuromuscular junctions, and glial dynamics

Watch now